Last reviewed · How we verify
FB2001 for inhalation
At a glance
| Generic name | FB2001 for inhalation |
|---|---|
| Also known as | DC402234 |
| Sponsor | Frontier Biotechnologies Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of FB2001 for Inhalation in Healthy Chinese Adults (PHASE1)
- Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 (PHASE2, PHASE3)
- Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FB2001 for inhalation CI brief — competitive landscape report
- FB2001 for inhalation updates RSS · CI watch RSS
- Frontier Biotechnologies Inc. portfolio CI